Michael Barbella, Managing Editor05.13.24
Vektor Medical is sharing study data demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.
The study, “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types. Designed to evaluate the impact of AI ECG mapping on time to ablation, procedural duration, and fluoroscopy, key data points from the study demonstrate vMap’s ability to deliver:
“A 22.6% reduction in procedure duration is significant,” said Dr. Sutton Fox, University of California, San Diego. “By employing AI ECG arrhythmia mapping using 12-lead ECG data, the study shows increased procedural efficiency and improved patient safety by limiting exposure to fluoroscopy. These advantages can drastically improve lab throughput and increase patient access to treatment.”
Published in the Journal of Cardiovascular Electrophysiology (JACE), the study is the third peer-reviewed trial since late 2021 that shows vMap’s potential to help physicians rapidly and accurately identify arrhythmia source locations. A September 2022 article published in Circulation: Arrhythmia and Electrophysiology indicated that vMap’s computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. An October 2021 article published in Heart Rhythm O2 demonstrated that a workflow involving computational ECG mapping and protocol-guided respiratory gating is feasible and safe and may improve stereotactic ablative radiotherapy planning.
“As the patient population suffering from cardiac arrhythmias continues to increase, reducing treatment procedure times without compromising outcomes is critical,” Vektor Medical CEO Rob Krummen stated. “The data published in JACE further validates vMap’s ability to do precisely that. EPs can rely on vMap to reduce procedure times with increased confidence in positive outcomes. This evidence of impact is driving the adoption of vMap throughout the United States in health systems.”
vMap is the a U.S. Food and Drug Administration-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing only a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway, according to Vektor Medical.
Headquartered in San Diego, Vektor Medical has developed artificial intelligence-based, non-invasive arrhythmia analysis technology—vMap—designed to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.
The study, “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types. Designed to evaluate the impact of AI ECG mapping on time to ablation, procedural duration, and fluoroscopy, key data points from the study demonstrate vMap’s ability to deliver:
- A 19% reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p = 0.02)
- A 22.6% reduction in procedure duration (233 ± 51 vs. 301 ± 83 min, p < 0.001)
- A 43.7% reduction in fluoroscopy (18.7 ± 13.3 vs. 33.2 ± 18.0 min, p < 0.001)
“A 22.6% reduction in procedure duration is significant,” said Dr. Sutton Fox, University of California, San Diego. “By employing AI ECG arrhythmia mapping using 12-lead ECG data, the study shows increased procedural efficiency and improved patient safety by limiting exposure to fluoroscopy. These advantages can drastically improve lab throughput and increase patient access to treatment.”
Published in the Journal of Cardiovascular Electrophysiology (JACE), the study is the third peer-reviewed trial since late 2021 that shows vMap’s potential to help physicians rapidly and accurately identify arrhythmia source locations. A September 2022 article published in Circulation: Arrhythmia and Electrophysiology indicated that vMap’s computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. An October 2021 article published in Heart Rhythm O2 demonstrated that a workflow involving computational ECG mapping and protocol-guided respiratory gating is feasible and safe and may improve stereotactic ablative radiotherapy planning.
“As the patient population suffering from cardiac arrhythmias continues to increase, reducing treatment procedure times without compromising outcomes is critical,” Vektor Medical CEO Rob Krummen stated. “The data published in JACE further validates vMap’s ability to do precisely that. EPs can rely on vMap to reduce procedure times with increased confidence in positive outcomes. This evidence of impact is driving the adoption of vMap throughout the United States in health systems.”
vMap is the a U.S. Food and Drug Administration-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing only a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway, according to Vektor Medical.
Headquartered in San Diego, Vektor Medical has developed artificial intelligence-based, non-invasive arrhythmia analysis technology—vMap—designed to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.